# A Trial Comparing Efficacy and Safety of GZR101 and IDegAsp in Insulin Naïve or Insulin Treated Subjects with T2DM

> **NCT06199505** · PHASE2 · COMPLETED · sponsor: **Gan and Lee Pharmaceuticals, USA** · enrollment: 153 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** GZR101
- **DRUG:** insulin degledec/insulin aspart

## Key facts

- **NCT ID:** NCT06199505
- **Lead sponsor:** Gan and Lee Pharmaceuticals, USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-11-21
- **Primary completion:** 2024-06-28
- **Final completion:** 2024-07-12
- **Target enrollment:** 153 (ACTUAL)
- **Last updated:** 2025-01-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06199505

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06199505, "A Trial Comparing Efficacy and Safety of GZR101 and IDegAsp in Insulin Naïve or Insulin Treated Subjects with T2DM". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT06199505. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*